Clinical trials: Pancreatic Disorders
Cystic Fibrosis
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
The purpose of this study is to evaluate of the safety, efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) effects of lumacaftor (VX-809) alone and when coadministered with ivacaftor (VX-770) in participants with cystic…
- Trial name
- NCT01225211
- Testing
- Lumacaftor, Ivacaftor
- Where
- 55 sites in United States, Australia and 5 more
- Volunteers
- 312 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Melanoma, Prostate Cancer
An Expanded Access Program for AM0010 (Pegilodecakin)
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- NCT03554434
- Testing
- AM0010
- Sponsor
- Eli Lilly and Company
Pancreatic Insufficiency
Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis
This study will provide efficacy data for Creon 40,000 in CP subjects as well as long-term safety data. During the long-term treatment with Creon 40,000 nutritional parameters will be assessed and correlated with CFA.
- Trial name
- NCT00705978
- Testing
- Pancreatin
- Where
- 11 sites in India
- Volunteers
- 62 people
- Sponsor
- Abbott Products
Pancreatic Cancer
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with…
- Trial name
- NCT04390399
- Testing
- N-803, Aldoxorubicin HCl, PD-L1 t-haNK
- Where
- 4 sites in United States
- Volunteers
- 328 people
- Sponsor
- ImmunityBio, Inc.
Cystic Fibrosis
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease.
- Trial name
- CARE-CF1 (NCT03000348)
- Testing
- Cysteamine
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- NovaBiotics Ltd.
Cystic Fibrosis
Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease
The purpose of this trial is to evaluate the effects of a single dose of denufosol versus placebo on mucociliary clearance in patients with mild to moderate CF lung disease
- Trial name
- NCT00425165
- Testing
- denufosol tetrasodium (INS37217) Inhalation Solution
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
CHF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases.
- Trial name
- NCT04010799
- Testing
- CHF 6333
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Metastatic Sarcoma, Esophageal Cancer
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to…
- Conditions
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- PHANTOM (NCT06298916)
- Testing
- 64Cu-LNTH-1363S
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Lantheus Medical Imaging
Pancreatic Cancer
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
The first in human clinical study is planned as an open-label, dose-escalation, and dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer.
- Trial name
- NCT05141149
- Testing
- PBP1510 (400mg/16mL), Gemcitabine (1000 mg/m^2)
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 80 people
- Sponsor
- Prestige Biopharma Limited
Tumors, Glioma
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in…
- Conditions
- Tumors, Glioma, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00338026
- Testing
- ECO-4601
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Thallion Pharmaceuticals
Pancreatic Cancer, Unresectable Pancreatic Cancer
Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer
- Conditions
- Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT06026943
- Testing
- DaRT seeds insertion
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Alpha Tau Medical LTD.
Cystic Fibrosis, Mucociliary Clearance
A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
The purpose of this study is to evaluate the safety and tolerability of GS-9411 in patients with Cystic Fibrosis. GS-9411 is a sodium channel inhibitor, that may restore airway hydration and mucociliary clearance in the lung.
- Trial name
- NCT01025713
- Testing
- GS-9411
- Where
- Australia
- Sponsor
- Gilead Sciences
Adult Patients at High Risk of Sepsis
Serial Measurement of Pancreatic Stone Protein (PSP) for Sepsis Early Detection in ICU Patients
In this study, 250 patients with high-risk of sepsis will be enrolled, including ≥ 50 subjects with confirmed sepsis. Diagnostic criteria for sepsis should meet the Third International Consensus Definitions for Sepsis and Septic…
- Trial name
- NCT07232784
- Testing
- blood sampling
- Where
- 3 sites in China
- Volunteers
- 250 people
- Sponsor
- Fapon Biotech Inc.
Pancreatic Cancer, Unresectable Pancreatic Cancer
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer
- Conditions
- Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT05657743
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- 2 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Alpha Tau Medical LTD.
Cystic Fibrosis
Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
Prospective, randomized, placebo controlled, phase II clinical study of subjects crossing over from an approved inhaled antibiotic to inhaled nitric oxide as compared to a placebo control arm.
- Trial name
- NCT02498535
- Testing
- Nitric Oxide 160 ppm
- Where
- 7 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- Novoteris, LLC
Persistent Infection, Cystic Fibrosis
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.
- Trial name
- NCT06159725
- Testing
- CMTX-101
- Where
- 23 sites in United States
- Volunteers
- 43 people
- Sponsor
- Clarametyx Biosciences, Inc.
Thoracic Cancer, Pancreatic Cancer Non-resectable
Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System
This study with Chair-Based, Gantry-less Proton System (CBGS) (aka P-CURE Proton Beam Therapy System or Fixed Beam Chair-based Delivery System) is composed of 3 arms, as following: ARM1: Patients with locally recurrent…
- Conditions
- Thoracic Cancer, Pancreatic Cancer Non-resectable, Brain Cancer, Head Cancer
- Trial name
- PPTS (NCT05549414)
- Testing
- Proton Radiation
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- P-Cure
Cystic Fibrosis
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).
- Trial name
- NCT05844449
- Testing
- VNZ/TEZ/D-IVA
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 174 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic…
- Conditions
- Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- Trial name
- NCT06782555
- Testing
- Evofosfamide, Zalifrelimab, Balstilimab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- ImmunoGenesis
Liver Cancer, Pancreas Cancer
A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain
A prospective, multicenter, self-control clinical trial aim to enroll 110 patients suffered from upper abdominal (liver, pancreas, stomach, etc.) cancers .
- Conditions
- Liver Cancer, Pancreas Cancer, Stomach Cancer, Bile Duct Cancer
- Trial name
- NCT04014478
- Testing
- Endovascular Denervation
- Volunteers
- 110 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.